酒精使用障碍渴求与阿坎酸治疗反应的生物标志物:多组学见解
本研究基于Mayo Clinic阿坎酸试验(442例开放标签,治疗3个月)的多组学数据,探索酒精渴求强度与治疗反应的生物标志物。基线渴求强度是复饮的最显著临床预测因子(p=9.36E-06);基线血浆HSD11B1水平与渴求强度及阿坎酸治疗结局相关,基线血浆皮质醇与渴求强度正相关。全基因组关联研究在14号染色体KHNYN/CBLN3基因簇发现与血浆皮质醇及治疗结局相关的显著信号;患者来源iPSC功能基因组研究提示KHNYN和CBLN3可能调控皮质醇代谢与干扰素信号。
要点
- 基线渴求强度是复饮的最显著临床预测因子(p=9.36E-06)。
- 基线血浆HSD11B1水平与渴求强度及阿坎酸治疗结局相关。
- 14号染色体KHNYN/CBLN3基因簇SNP与血浆皮质醇及阿坎酸治疗结局相关。
核心结论
- 基线渴求强度是复饮的最显著临床预测因子(p=9.36E-06)。
- 基线血浆HSD11B1水平与渴求强度及阿坎酸治疗结局相关,基线血浆皮质醇与渴求强度正相关。
- 14号染色体KHNYN/CBLN3基因簇的显著信号与血浆皮质醇及阿坎酸治疗结局相关,iPSC研究提示其可能调控皮质醇代谢与干扰素信号。
研究设计与样本
- 基于Mayo Clinic阿坎酸研究的开放标签试验,共442例参与者接受阿坎酸治疗3个月。
- 收集包括酒精消耗与渴求强度在内的临床数据,基线血浆样本采用OLINK「Explore Inflammation」panel分析。
- 采用患者来源诱导多能干细胞(iPSC)作为功能基因组模型,并进行血浆皮质醇的全基因组关联研究(GWAS)。
主要发现
- 基线渴求强度是复饮的最显著临床预测因子(p: 9.36E-06)。
- 基线血浆HSD11B1水平与渴求强度及阿坎酸治疗结局相关。
- 基线血浆皮质醇水平与渴求强度呈正相关。
- 血浆皮质醇GWAS在14号染色体KHNYN和CBLN3基因簇发现显著信号,该SNP亦与阿坎酸治疗结局相关。
- 患者来源iPSC功能基因组研究提示KHNYN和CBLN3可能调控皮质醇代谢与干扰素信号。
关键数值与推荐
- 基线渴求强度预测复饮的p值为9.36E-06。
- 共442例参与者接受阿坎酸治疗3个月。
临床怎么用
- 基线渴求强度可作为阿坎酸治疗中复饮风险的重要临床评估指标。
- 基线血浆HSD11B1与皮质醇水平及KHNYN/CBLN3基因簇变异可能辅助识别阿坎酸治疗反应差异,但尚需进一步验证。
局限性
- 本研究为开放标签试验,未设安慰剂对照。
- 生物标志物与治疗反应的相关性需在独立样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date, no objective biochemical markers have been linked to alcohol craving intensity or response to drug treatment for alcohol use disorder (AUD). To address this gap, we aimed to identify potential biomarkers associated with alcohol craving intensity using multi-omics data from the Mayo Clinic acamprosate study-the largest acamprosate trial of its kind and the only one with multi-omics data. In this open-label trial, all 442 participants received acamprosate treatment for three months, during which we collected extensive clinical data, including alcohol consumption and craving intensity. Baseline plasma samples were analyzed using the OLINK "Explore Inflammation" panel, and we employed patient-derived induced pluripotent stem cells (iPSCs) as a functional genomic model. Our findings revealed that baseline craving intensity was the most significant clinical predictor of relapse (p: 9.36E-06). Baseline plasma levels of HSD11B1, an enzyme that converts inactive cortisone to active cortisol, were associated with both craving intensity and acamprosate treatment outcomes. Additionally, baseline plasma cortisol levels showed a positive correlation with craving intensity. Notably, a genome-wide association study (GWAS) for plasma cortisol levels identified significant signals within the KHNYN and CBLN3 gene cluster on chromosome 14. Even more striking, this SNP was also associated with acamprosate treatment outcomes. Functional genomic studies using patient-derived iPSC further suggest that KHNYN and CBLN3 could regulate cortisol metabolism and interferon signaling. In summary, this study leverages multi-omics data from one of the most extensive acamprosate trials to date to identify potential biomarkers for alcohol craving intensity and treatment response.
引用
- Ho MF, Zhang C, Coombes BJ, et al. Biomarker for craving and acamprosate treatment response in patients with alcohol use disorder: insights from multi-omics. Mol Psychiatry. 2026. PMID: 41741704. doi:10.1038/s41380-026-03506-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。